This included AML (GLP-1 users HR 0.81, 95% CI 0.52–1.27, p = 0.354; SGLT2 inhibitor users HR 1.22, 95% CI 0.84–1.77, p = 0.298), CML (GLP-1 users HR 1.06, 95% CI 0.58–1.92, p = 0.857; SGLT2 inhibitor users HR 1.23, 95% CI 0.74–2.06, p = 0.428), and MDS (GLP-1 users HR 0.98, 95% CI 0.68–1.40, p = 0.891; SGLT2 inhibitor users HR 1.0, 95% CI 0.73–1.36, p = 0.996). Here, GLP1R is linked to chronic myelogenous leukemia, BCR-ABL1 positive.